Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1124105 · FYE Dec 31 · Prices AT CLOSE 2026-08-28 (USD) Last $6.59 · Day −1.35% · Mkt cap $745M · P/E (FY) 334.0× · 1Y −20.4% · Off 52W high −30.0% · Vol (1Y) 58.1% Price2023-10-31 → 2026-08-28 GYRE close: $6.7 on 2023-10-31 to $6.6 on 2026-08-28. Split-adj closes · 240 of 704 · price returnⓘ At a glance | Short interest1.6% of sh out | | Days to cover31.1d | | 13F net flow (QoQ)+0.07% | | Top-10 13F concentration92.2% | | Next report (est.)2026-11-07 |
SI 2026-08-14 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | P/E (FY)334.0× | | Sales (TTM)$116.4M | | Earnings (TTM)-$25.7M | | ROE11.7% | | Net margin8.5% | | ROIC9.7% | | EPS growth 3Y−12.6% | | Sales growth 3Y4.5% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD−6.7% | | 1Y−20.4% | | Since incept. (ann.)−0.7% |
Total return · from 2023-10-31ⓘ Risk | Ann. volatility (1Y)58.1% | | Ann. volatility (3Y)100.3% | | Sharpe (1Y)−0.08 | | Sharpe (3Y)0.49 | | Max drawdown (1Y)−37.3% | | Max drawdown (3Y)−81.3% | | Beta (3Y vs SPY)4.82 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 984,204 | $7M | 1.02% | new | | BlackRock, Inc. | 758,630 | $5M | 0.78% | +5.3% | | GEODE CAPITAL MANAGEMENT, LLC | 431,414 | $3M | 0.44% | +1.9% | | STATE STREET CORP | 216,326 | $2M | 0.22% | +7.0% | | SBI Securities Co., Ltd. | 170,837 | $1M | 0.18% | +4.9% | | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 165,238 | $1M | 0.17% | −2.3% | | VANGUARD FIDUCIARY TRUST CO | 137,682 | $959,644 | 0.14% | new | | NORTHERN TRUST CORP | 133,841 | $932,872 | 0.14% | +3.9% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-08-07 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-06-30 | 2026-08-07 | −$0.12 | — | $29.1M | −2.1% | | 2026-03-31 | 2026-05-07 | −$0.10 | — | $22.5M | +2.1% | | 2025-12-31 | 2026-03-12 | — | — | $34.2M | +22.8% | | 2025-09-30 | 2025-11-07 | $0.03 | +200.0% | $30.6M | +19.9% |
As-reported XBRL · next 2026-11-07 est.ⓘ Segment mixFY2025 (ended Dec 2025) Gyre Pharmaceuticals 100% business · TAGGED revenueⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
|
